Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Share-based Compensation (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Share-based Compensation for 6 consecutive years, with $4.5 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 42.67% to $4.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $15.3 million through Dec 2025, up 88.07% year-over-year, with the annual reading at $15.3 million for FY2025, 88.07% up from the prior year.
  • Share-based Compensation for Q4 2025 was $4.5 million at Inhibikase Therapeutics, roughly flat from $4.5 million in the prior quarter.
  • The five-year high for Share-based Compensation was $7.9 million in Q4 2024, with the low at $30697.0 in Q2 2024.
  • Average Share-based Compensation over 5 years is $1.3 million, with a median of $140395.5 recorded in 2022.
  • The sharpest move saw Share-based Compensation plummeted 79.15% in 2022, then surged 13610.6% in 2025.
  • Over 5 years, Share-based Compensation stood at $265850.0 in 2021, then plummeted by 62.25% to $100363.0 in 2022, then grew by 21.81% to $122249.0 in 2023, then soared by 6369.14% to $7.9 million in 2024, then tumbled by 42.67% to $4.5 million in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $4.5 million, $4.5 million, and $4.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.